FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012087592> ?p ?o ?g. }

• W2012087592 endingPage "62" @default.
• W2012087592 startingPage "55" @default.
• W2012087592 abstract "Background Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. Methemoglobinemia is a known complication of dapsone, but its true frequency and pathogenesis in childhood cancer patients are unknown. Additionally, practice guidelines for evaluation and management of dapsone-induced methemoglobinemia are not available. Procedure We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels. Ten children with ALL receiving trimethoprim-sulfamethaxazole (TMP-SMX) were studied as controls. All patients underwent physical examination, pulse oximetry, and methemoglobin (metHb) estimation. Commercially available assay was used to measure Cb5R levels. Results Three (20%) patients receiving dapsone developed symptomatic methemoglobinemia. Average duration of dapsone prophylaxis prior to diagnosis was 6.6 weeks (range 3.5–10 weeks). Mean metHb level in symptomatic patients was 11.67%; 95% confidence interval (CI) 0–25.79 (range 7–18%), and 1.37%; 95% CI 0.6–2.14 (range 0.02–3%) in asymptomatic patients (P = 0.09), whereas the mean metHb level in the control group was 0.54%; 95% CI 0.35–0.73 (range 0.1–0.8%) (asymptomatic vs control P < 0.0001). Mean Cb5R level in symptomatic patients was 8.6 IU/g Hb; 95% CI 3.4–13.7 (range 6.9–10.9) compared to 12.5 IU/g Hb; 95% CI 11.1–13.9 (range 10.8–14.6) in asymptomatic patients (P = 0.06). Two symptomatic patients had Cb5R levels at or below 50% of normal, consistent with heterozygosity. Parental studies for Cb5R levels were suggestive of a carrier state in one of each patient's parents. Conclusions Heterozygosity for Cb5R deficiency may pre-dispose to methemoglobinemia even on a thrice-weekly regimen of dapsone. Such individuals should avoid subsequent exposure to oxidant agents, if possible. Children with ALL tend to be symptomatic at low levels of metHb and may have delayed detection of methemoglobinemia. Hence, frequent monitoring of patients receiving dapsone is recommended. Monitoring guidelines for dapsone prophylaxis are proposed. © 2004 Wiley-Liss, Inc." @default.
• W2012087592 created "2016-06-24" @default.
• W2012087592 creator A5029639633 @default.
• W2012087592 creator A5029991649 @default.
• W2012087592 creator A5048306141 @default.
• W2012087592 creator A5050888466 @default.
• W2012087592 creator A5084991338 @default.
• W2012087592 date "2004-01-01" @default.
• W2012087592 modified "2023-09-27" @default.
• W2012087592 title "Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone forpneumocystis carinii pneumonia (PCP) prophylaxis: A correlation with cytochrome b5 reductase (Cb5R) enzyme levels" @default.
• W2012087592 cites W174981741 @default.
• W2012087592 cites W1786228971 @default.
• W2012087592 cites W195727234 @default.
• W2012087592 cites W1971109590 @default.
• W2012087592 cites W1978175669 @default.
• W2012087592 cites W1978715187 @default.
• W2012087592 cites W1980174425 @default.
• W2012087592 cites W1991992428 @default.
• W2012087592 cites W1993404332 @default.
• W2012087592 cites W2003966794 @default.
• W2012087592 cites W2008217096 @default.
• W2012087592 cites W2010855055 @default.
• W2012087592 cites W2018181392 @default.
• W2012087592 cites W2022899306 @default.
• W2012087592 cites W2034495440 @default.
• W2012087592 cites W2035959796 @default.
• W2012087592 cites W2040627918 @default.
• W2012087592 cites W2043465770 @default.
• W2012087592 cites W2044699515 @default.
• W2012087592 cites W2051105907 @default.
• W2012087592 cites W2057866669 @default.
• W2012087592 cites W2067290227 @default.
• W2012087592 cites W2069315040 @default.
• W2012087592 cites W2072926183 @default.
• W2012087592 cites W2078518565 @default.
• W2012087592 cites W2080646634 @default.
• W2012087592 cites W2107746427 @default.
• W2012087592 cites W2111378962 @default.
• W2012087592 cites W2114236188 @default.
• W2012087592 cites W2154208672 @default.
• W2012087592 cites W2167437946 @default.
• W2012087592 cites W2219927379 @default.
• W2012087592 cites W2342351290 @default.
• W2012087592 cites W3021051226 @default.
• W2012087592 cites W324869811 @default.
• W2012087592 cites W4232772744 @default.
• W2012087592 cites W4236564545 @default.
• W2012087592 cites W4236887613 @default.
• W2012087592 cites W4244624554 @default.
• W2012087592 cites W49613876 @default.
• W2012087592 cites W96484744 @default.
• W2012087592 cites W4243066188 @default.
• W2012087592 doi "https://doi.org/10.1002/pbc.20164" @default.
• W2012087592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15390276" @default.
• W2012087592 hasPublicationYear "2004" @default.
• W2012087592 type Work @default.
• W2012087592 sameAs 2012087592 @default.
• W2012087592 citedByCount "34" @default.
• W2012087592 countsByYear W20120875922012 @default.
• W2012087592 countsByYear W20120875922013 @default.
• W2012087592 countsByYear W20120875922014 @default.
• W2012087592 countsByYear W20120875922016 @default.
• W2012087592 countsByYear W20120875922017 @default.
• W2012087592 countsByYear W20120875922020 @default.
• W2012087592 countsByYear W20120875922021 @default.
• W2012087592 countsByYear W20120875922022 @default.
• W2012087592 countsByYear W20120875922023 @default.
• W2012087592 crossrefType "journal-article" @default.
• W2012087592 hasAuthorship W2012087592A5029639633 @default.
• W2012087592 hasAuthorship W2012087592A5029991649 @default.
• W2012087592 hasAuthorship W2012087592A5048306141 @default.
• W2012087592 hasAuthorship W2012087592A5050888466 @default.
• W2012087592 hasAuthorship W2012087592A5084991338 @default.
• W2012087592 hasConcept C126322002 @default.
• W2012087592 hasConcept C141071460 @default.
• W2012087592 hasConcept C203014093 @default.
• W2012087592 hasConcept C26865036 @default.
• W2012087592 hasConcept C2777559004 @default.
• W2012087592 hasConcept C2777640609 @default.
• W2012087592 hasConcept C2777737778 @default.
• W2012087592 hasConcept C2777910003 @default.
• W2012087592 hasConcept C2777914695 @default.
• W2012087592 hasConcept C2778917026 @default.
• W2012087592 hasConcept C2993443204 @default.
• W2012087592 hasConcept C42219234 @default.
• W2012087592 hasConcept C71924100 @default.
• W2012087592 hasConcept C90924648 @default.
• W2012087592 hasConceptScore W2012087592C126322002 @default.
• W2012087592 hasConceptScore W2012087592C141071460 @default.
• W2012087592 hasConceptScore W2012087592C203014093 @default.
• W2012087592 hasConceptScore W2012087592C26865036 @default.
• W2012087592 hasConceptScore W2012087592C2777559004 @default.
• W2012087592 hasConceptScore W2012087592C2777640609 @default.
• W2012087592 hasConceptScore W2012087592C2777737778 @default.
• W2012087592 hasConceptScore W2012087592C2777910003 @default.
• W2012087592 hasConceptScore W2012087592C2777914695 @default.
• W2012087592 hasConceptScore W2012087592C2778917026 @default.
• W2012087592 hasConceptScore W2012087592C2993443204 @default.

• next